Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Ms. Emma Natasha Walmsley | CEO & Director | 5.82M | 1.12M | 1969 |
| Ms. Julie Belita Brown A.C.A. | CFO & Executive Director | 5.39M | -- | 1962 |
| Ms. Shobie Ramakrishnan | Chief Digital & Technology Officer | -- | -- | 1971 |
| Mr. Tony Wood | Chief Scientific Officer and Head of R&D | -- | -- | -- |
| Mr. James Ford | Senior VP & Group General Counsel of Legal & Compliance | -- | -- | -- |
| Ms. Sally Jackson | Senior Vice President of Global Communications & CEO Office | -- | -- | -- |
| Mr. David Simon Redfern BSc (Hons), CA | President of Corporate Development | -- | -- | 1966 |
| Ms. Diana Conrad | Chief People Officer | -- | -- | -- |
| Mr. Philip C. Thomson | President of Global Affairs | -- | -- | -- |
| Mr. Luke V. Miels | Chief Commercial Officer | -- | -- | 1975 |
GSK plc
- Sector:
- Healthcare
- Industry: Drug Manufacturers - General
- Full Time Employees:
- 68,629
Description
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and Relation Therapeutics, using their Lab in the Loop platform to discover novel targets for osteoarthritis, systemic sclerosis and other fibrotic mechanisms, supporting data-tech driven approach in respiratory, immunology and inflammation; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, the United Kingdom.
Corporate Governance
Upcoming Events
April 10, 2025 at 12:00 AM UTC
Dividend Date
April 30, 2025 at 7:30 AM UTC
GSK plc Earnings Date